Navigation Links
Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
Date:4/27/2008

TAMPA, Fla., April 27 /PRNewswire-FirstCall/ -- Calvin A. Grant, MD, Retina Macular Care, presented the results from his 60-patient retrospective case control study that was designed to evaluate the adjuvant use of Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R) (ranibizumab) treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) in an oral poster presentation at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Dr. Grant reported patients who received Xibrom in addition to Lucentis (the Combination Group) required 1.6 +/- 0.69 injections of Lucentis during the six-month study period, while patients who received Lucentis only received 4.5 +/- 0.41 injections (p=0.0002). The original abstract, which was published in February 2008, stated there was a numerical trend in favor of the Combination Group on improvement in visual acuity but this difference did not achieve statistical significance. However, upon rigorous review and further statistical analysis, the data has shown the Combination Group did show a statistically significant improvement in visual acuity. In the Combination Group, mean visual acuity increased 1.2 +/- 1.64 lines compared with 0.06 +/-0.66 lines in patients in the Lucentis-only group (p=0.001).

The study results were gathered from 60 patients receiving Lucentis therapy for wet AMD. Patients were monitored monthly using optical coherence tomography (OCT) and fluorescein angiography. When subretinal fluid from leaking vessels was detected by OCT, patients were re-injected with Lucentis. 30 patients received Xibrom dosed twice daily in addition to the Lucentis injection (the Combination Group), and their results were compared to 30 patients who received Lucentis only. There were no adverse events associated with the extended topical administration of bromfenac.

ISTA Pharmaceuticals (Nasdaq:

SOURCE ISTA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
4. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
5. Chinese SFDA Grants Immtech Fast Track Status
6. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
9. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
10. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
11. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... CHICAGO , June 5 Scientists from ... presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used ... slightly poorer survival rate in post-menopausal women with early stage ... findings were announced today at the 2010 American Society of ...
... BARBARA, Calif. , June 4 Abviva, Inc. (Pink ... of breast cancer related applications of Mammastatin, today provided further details ...   , , , ... appoints W.T. Uniack & Co. as its independent auditor. ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4Abviva Engages W.T. Uniack & Co. As Independent Auditor 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Niche Profit ... Adam Short that is designed to provide a blueprint for ... the attention of Shane Michaels, prompting an investigative review. ... , “What really speaks volumes about the success of the ... and strategies included in it have stayed effective even through ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Hook Your Ex, a ... get ex’s to feel emotionally hungry for their partner, to the ... chance. This little trick has been taught to hundreds of ... a quick Hook Your Ex review , Shane Michaels agrees ... suffering pain from a breakup a second chance at getting back ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Cosmetic ... benefit both patients and doctors. Doctors will be able ... to leave reviews , which guarantees their authenticity. ... options on the site to receive information that has ... This unprecedented validation system allows Cosmetic Town to filter ...
(Date:7/31/2014)... Farmington, NY (PRWEB) July 31, 2014 ... restaurants incorporating Pioneer Millworks’ reclaimed wood to create ... the environment. Their newest location features reclaimed ... the restaurant, with custom selected mixed softwoods flowing ... trusses crafted by Pioneer Millworks’ sister company ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2
... have raised questions regarding differences in quality of care ... In fact, a growing body of health services research ... the weekend and increased mortality. This "weekend effect" has ... specific intensive treatments and procedures. , Two recent studies ...
... the March 1 issue of the journal SLEEP ... promising model for addressing adolescent sleep problems, given ... healthy sleep knowledge and practice. , The program, ... period, had a high retention rate of 83 percent ...
... green vegetables such as broccoli and cabbage could ... cancer researchers. Tests on mice suggest that these ... safely and effectively than conventional therapy. , "There ... that trigger melanoma," said Gavin Robertson, associate professor ...
... Bethesda, MD (March 1, 2009) Although the ... is well established, studies investigating the association between ... (BE) and esophageal adenocarcinoma (EAC) have reported inconsistent ... of alcohol on BE, especially related to alcohol ...
... Brian Schweitzer, Chair of the Democratic Governors Association, today ... Gov. Kathleen Sebelius as Secretary of Health and Human ... Kathleen Sebelius is an excellent choice to lead the ... our health care system, Governor Sebelius will bring a ...
... precautions should be abandoned, experts note , , SATURDAY, ... trip is as important as packing the right clothes. ... doesn,t mean it,s safe," Laura Gonzalez, a nurse with The ... said in a news release issued by the school. "You ...
Cached Medicine News:Health News:Patients with GI bleeding admitted on the weekend have higher death rate 2Health News:Patients with GI bleeding admitted on the weekend have higher death rate 3Health News:School-based intervention is a promising model for improving adolescent sleep habits 2Health News:School-based intervention is a promising model for improving adolescent sleep habits 3Health News:Vegetable-based drug could inhibit melanoma 2Health News:Alcohol types and socioeconomic status are associated with Barrett's esophagus risk 2Health News:Alcohol types and socioeconomic status are associated with Barrett's esophagus risk 3Health News:Travel Safety Can Be a Passport to Good Health 2
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Endocrine Control is a human based product designed to monitor plasma catecholamine testing procedures by HPLC. The analytes are spiked at critical concentrations to cover the dynamic range...
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
Medicine Products: